Medication info
Pregabalin Capsule 75mg (Pregabalin)

Pregabalin Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Gooju Pharmaceutical Co., Ltd.
Appearance
Hard capsule with reddish-brown upper and white lower part containing white powder that appears white or light yellow.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201902240 · Approved 2019.04.12 · Insurance code 669805290

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial seizures in epilepsy; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), which may be increased to 150 mg twice daily (300 mg daily) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased to 225 mg twice daily (450 mg daily) within 1 week. Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Gooju Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial seizures in epilepsy; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it is effective as an adjunct to partial seizures in epilepsy patients, whether or not they have secondary generalization. It also helps alleviate symptoms of fibromyalgia. Overall, it contributes to the improvement of various symptoms related to neuropathy and is used safely to manage these symptoms.

How to take

Adult dose

The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), which may be increased to 150 mg twice daily (300 mg daily) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased to 225 mg twice daily (450 mg daily) within 1 week. Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so it is important to closely monitor any abnormal changes in mood or behavior during treatment. Patients with hypersensitivity to this medication or genetic conditions such as lactose intolerance should not use it. Diabetic patients may need to adjust their blood sugar control medications due to potential weight gain. If serious allergic reactions such as angioedema occur, the use of this medication should be stopped immediately. Elderly patients may have an increased risk of falls due to dizziness or drowsiness and should be monitored closely. Visual disturbances or changes in vision may occur, and if symptoms are severe, discontinuation of the medication should be considered. Withdrawal symptoms such as insomnia, headaches, and anxiety may occur when discontinuing the medication, so consultation with a healthcare provider is recommended. Patients with a history of substance abuse may be at higher risk for misuse of this medication, so it should be used cautiously. Dose adjustments may be necessary for patients with impaired renal function. Patients with cardiovascular conditions should use this medication with caution. Caution is advised when taking this medication together with opioid analgesics due to increased risk of central nervous system depression. Patients with compromised respiratory function or elderly individuals are at risk of severe respiratory depression and may need dose adjustments. Pregnant women are advised not to use this medication during early pregnancy due to potential risks of fetal malformation, and women of childbearing age should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or stopping the medication, as it can be transmitted through breast milk. It is safest to avoid hazardous activities such as driving or operating machinery until dizziness or drowsiness subside after taking this medication. Severe skin reactions may occur; report any skin abnormality immediately to a healthcare provider. In case of overdose, symptoms such as drowsiness, confusion, and depression may manifest, and treatment such as blood dialysis may be required.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, spatial disorientation, irritability, depression, euphoria, decreased libido, insomnia, depersonalization, hyperaesthesia, restlessness, anxiety, mood fluctuations, emotional lethargy, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, impaired coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonic jerks, diminished reflexes, motor abnormalities, psychomotor agitation, orthostatic dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, exercise intolerance, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, peripheral vision loss, visual field defects, photopsia, dry eyes, ocular swelling, decreased vision, eye pain, eye fatigue, increased tear secretion, ocular irritation, mydriasis, changes in depth perception while vibrating, strabismus, brightness of vision, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, joint pain, back pain, limb pain, cervical spasm, joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, kidney failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, angioedema, allergic reactions, headache, loss of consciousness, mental disorder, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, facial swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), mood disorders, drowsiness, confusion, depression, agitation, restlessness, exacerbation of seizures, ataxia, difficulties in spoken language, bloody stools, increased BUN, dysuria, tinnitus, skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, preferably in a cool place between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

Hard capsule with reddish-brown upper and white lower part containing white powder that appears white or light yellow.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.